Standard practice for treating ovarian cancer -- currently affecting 22,000+ American women -- is a combination of two drugs called Cisplatin and Taxol. The problem? Only 40% of women treated this way survive. We're an oncology company focused on helping those women respond more successfully to treatment by inhibiting STAT3, a mechanism found in 30+ cancer types. We've found that inhibiting this mechanism makes treatment 10-20% more effective, which would save thousands of lives per year.
Selected by the National Cancer Institute's PREVENT Cancer Preclinical Drug Development Program for breast cancer.
Founder has taken 10 approved drugs to the FDA & EMA and failed only once.
Received $3.7MM grant from EU supported fund in Poland for Triple Negative Breast Cancer Treatment.
Launched a public subsidiary on Warsaw- New Connect exchange under the symbol GLG.
Created a development agreement for diagnostics development with Helomics Corporation and Skyline Medical, Inc.
In 2018, completing and filing two additional grants with Quick Path program in Poland for ovarian, uterine, cervical (2017) and fallopian cancers.
Through our UK subsidiary, won £100K grant to apply the Gx-C3 platform for better outcomes in childhood brain tumors.
If we can isolate enough tissue to understand why 40% of women don't respond to the leading treatment -- which no one else has figured out yet -- we could move that percentage to between 45-50%. Combined with our STAT3 research, we think that in the next 5 years, we could raise that response rate to 60% - 70%. By combining this research with new combination therapies and diagnostics, we could permanently improve cancer treatment while aiming to achieve sales of $250 million in 5 years.